Long-term thermal stability of group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine

Human Vaccines

Volumn 3, Issue 1, 2007, Pages 27-32

  Lee, Shwu Maan ^a   Petermann, Robert ^b   Porte, Quallyna ^a   Berezuk, Greg ^a   Crowe, Brian ^b   Shirtz, John ^a  

^a Baxter BioScience   (United States)

^b BAXTER BIOSCIENCE   (Austria)

Author keywords

Conjugate; Immunogenicity; Meningococcal infections; Storage; Thermal stability; Vaccines

Indexed keywords

ALUMINUM; CARBOHYDRATE; GROUP C MENINGOCOCCAL POLYSACCHARIDE TETANUS TOXOID CONJUGATE VACCINE; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; NEISVAC C; POLYSACCHARIDE VACCINE; SODIUM CHLORIDE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENCY; DRUG STABILITY; DRUG STORAGE; FREEZING; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; ROOM TEMPERATURE; SERUM BACTERICIDAL ACTIVITY; STORAGE TEMPERATURE; SUSPENSION; THERMOSTABILITY; TIME;

EID: 33847052496     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.1.3749     Document Type: Article

References (18)

1. Galazka A, Milstien J, Zaffran M. Thermostability of vaccines. World Health Organization Global Progamme for Vaccines and Immunization 1998; 1-64.
2. Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR. Thermal stability of vaccines. J Pharm Sci 2003; 92:218-31.
3. Bishai DM, Bhatt S, Miller LT, Hayden GF. Vaccine storage practices in pediatric offices. Pediatrics 1992; 89:193-6.
4. Weir E, Hatch K. Preventing cold chain failure: Vaccine storage and handling. CMAJ 2004; 171:1050.
5. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, Cartwright K, Miller E. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183:160-3.
6. Richmond P, Borrow R, Findlow J, Martin S, Thornton C, Cartwright K, Miller E. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: Reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infect Immun 2001; 69:2378-82.
7. Jódar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002; 359:1499-508.
8. Corbel MJ. Reasons for instability of bacterial vaccines. Dev Biol Stand 1996; 87:113-24.
9. World Health Organization. Recommendations for the production and control of meningococcal group C conjugate vaccines. WHO Technical Report 2004, (Series 924, Annex 2).
10. 197 conjugate vaccines. Vaccine 2000; 19:716-25.
11. 197 conjugate vaccines. Biotechnol Appl Biochem 2001; 33:91-8.
12. Ho MM, Mawas F, Bolgiano B, Lemercinier X, Crane DT, Huskisson R, Corbel MJ. Physico-chemical and immunological examination of the thermal stability of tetanus toxoid conjugate vaccines. Vaccine 2002; 20:3509-22.
13. Jennings HJ, Lugowski C. Immunochemistty of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol 1981; 127:1011-8.
14. Michon F, Huang CH, Farley EK, Hronowski L, Di J, Fusco PC. Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: Effect of O-acetylation on the nature of the protective epitope. Dev Biol (Basel) 2000; 103:151-60.
15. Fusco PC, Michon F, Tai JY, Blake MS. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J Infect Dis 1997; 175:364-372.
16. Svennerholm L. Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta 1957; 24:604-11.
17. Jodar L, Griffiths E, Feavers I. Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines. Vaccine 2004; 22:1047-53.
18. Pöllabauer EM, Petermann R, Ehrlich HJ. Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: A meta-analysis of immunogenicity, safety and posology. Human Vaccines 2005; 1:131-9.